Kaviarasan Kuppan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kaviarasan Kuppan has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Sharmila Rajendran
Department of Biomedical Sciences, Faculty of Biomedical Sciences and Technology, Sri Ramachandra Institute of Higher Education and Research, Chennai, India
2 shared publications- Arun Dharmarajan
School of Human Sciences, The University of Western Australia, Perth, WA 6009, Australia
1 shared publication Hanuman Prasad Sharma
Scientist – II Bioanalytics Facility, Centralized Core Research Facility, All India Institute of Medical Sciences (AIIMS)
1 shared publication- Madhana Priya Nanda Kumar
Department of Biotechnology, Sri Ramachandra Institute of Higher Education and Research (DU), Porur, Chennai 600116, India
1 shared publication - Magesh Ramasamy
Department of Biotechnology, Faculty of Biomedical Sciences & Technology, Sri Ramachandra Institute of Higher Education and Research (DU)
1 shared publication - Priyanka Kannan
Department of Biotechnology, Sri Ramachandra Institute of Higher Education and Research (DU), Porur, Chennai 600116, India
1 shared publication
Latest Publications
- Open Access
- 15 May 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (10) , 4404
Molecular Modeling of N-Acetylglucosamine Binding to the I154R Mutant of NAGLU: Pathogenic Insights into Sanfilippo Syndrome Type B
Sanfilippo syndrome type B, also known as mucopolysaccharidosis type IIIB (MPS IIIB), is a rare autosomal recessive lysosomal storage disorder caused by mutations in the N-acetyl-α-D-glucosaminidase (NAGLU) gene, which encodes the enzyme α-N-acetylglucosaminidase. This enzyme is essential for degrading heparan sulfate. The deficiency leads to toxic accumulation within cells. To investigate the impact of NAGLU mutations, mutational data were retrieved from public databases including NCBI, UniProt, and HGMD. A total of 162 variants were evaluated using sequence-based prediction tools to identify deleterious mutations, followed by structure-based in silico analyses to assess changes in protein stability, biophysical properties, and ligand-binding potential. Among the analyzed mutations, the I154R variant was identified as the most deleterious, showing disease-associated characteristics, structural instability, and impaired functional properties. Molecular docking with N-acetylglucosamine (NAG) revealed binding affinities of −4.17 kcal/mol for the native protein and −3.97 kcal/mol for the I154R mutant, suggesting a retained yet slightly reduced binding potential. Molecular dynamics simulations supported these findings, indicating stable trajectories, favorable interaction profiles, and moderate flexibility for both complexes. These results enhance our understanding of NAGLU-related pathogenicity in MPS IIIB, contributing to improved health care strategies and offering a valuable foundation for future therapeutic developments targeting enzyme dysfunction in Sanfilippo syndrome type B.
- 15 May 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (10) , 4404
Open AccessMolecular Modeling of N-Acetylglucosamine Binding to the I154R Mutant of NAGLU: Pathogenic Insights into Sanfilippo Syndrome Type B
Sanfilippo syndrome type B, also known as mucopolysaccharidosis type IIIB (MPS IIIB), is a rare autosomal recessive lysosomal storage disorder caused by mutations in the N-acetyl-α-D-glucosaminidase (NAGLU) gene, which encodes the enzyme α-N-acetylglucosaminidase. This enzyme is essential for degrading heparan sulfate. The deficiency leads to toxic accumulation within cells. To investigate the impact of NAGLU mutations, mutational data were retrieved from public databases including NCBI, UniProt, and HGMD. A total of 162 variants were evaluated using sequence-based prediction tools to identify deleterious mutations, followed by structure-based in silico analyses to assess changes in protein stability, biophysical properties, and ligand-binding potential. Among the analyzed mutations, the I154R variant was identified as the most deleterious, showing disease-associated characteristics, structural instability, and impaired functional properties. Molecular docking with N-acetylglucosamine (NAG) revealed binding affinities of −4.17 kcal/mol for the native protein and −3.97 kcal/mol for the I154R mutant, suggesting a retained yet slightly reduced binding potential. Molecular dynamics simulations supported these findings, indicating stable trajectories, favorable interaction profiles, and moderate flexibility for both complexes. These results enhance our understanding of NAGLU-related pathogenicity in MPS IIIB, contributing to improved health care strategies and offering a valuable foundation for future therapeutic developments targeting enzyme dysfunction in Sanfilippo syndrome type B.
- Open Access
- 23 March 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1748000
Role play of regulatory T cells and resolvins in type 2 diabetes
Low-grade systemic inflammation is seen in type 2 diabetes mellitus (T2DM), which is also considered the underlying mechanism for the occurrence of major complications observed in these patients. In developing countries like India, prediabetes/insulin resistance is often overlooked. Specialized pro-resolving mediators (SPMs) are a family of anti-inflammatory lipid molecules that are needed to resolve inflammation to maintain immune balance and prevent complications due to DM. Treg cells are a subset of CD4 + T cells that express IL-2 receptor alpha chain CD25 and FOXP3 transcription factor to maintain immune tolerance during diabetes. In this context, the role of resolvins in the regulatory function of Treg cells assumes significance in the prevention and management of diabetic complications. In the current review, we explore the functions of Tregs and resolvins and their potential implications in managing insulin resistance, obesity, and type 2 diabetes.
- 23 March 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1748000
Open AccessRole play of regulatory T cells and resolvins in type 2 diabetes
Low-grade systemic inflammation is seen in type 2 diabetes mellitus (T2DM), which is also considered the underlying mechanism for the occurrence of major complications observed in these patients. In developing countries like India, prediabetes/insulin resistance is often overlooked. Specialized pro-resolving mediators (SPMs) are a family of anti-inflammatory lipid molecules that are needed to resolve inflammation to maintain immune balance and prevent complications due to DM. Treg cells are a subset of CD4 + T cells that express IL-2 receptor alpha chain CD25 and FOXP3 transcription factor to maintain immune tolerance during diabetes. In this context, the role of resolvins in the regulatory function of Treg cells assumes significance in the prevention and management of diabetic complications. In the current review, we explore the functions of Tregs and resolvins and their potential implications in managing insulin resistance, obesity, and type 2 diabetes.
- 20 July 2022
- Published by Elsevier in Experimental Eye Research
- Vol. 223, 109194
Integrative study of gene expression datasets in retinal samples of Diabetic Retinopathy
- 20 July 2022
- Published by Elsevier in Experimental Eye Research
- Vol. 223, 109194
Integrative study of gene expression datasets in retinal samples of Diabetic Retinopathy
- 1 May 2021
- Published by Elsevier in The International Journal of Biochemistry & Cell Biology
- Vol. 134, 105971
Microvascular cells: A special focus on heterogeneity of pericytes in diabetes associated complications
- 1 May 2021
- Published by Elsevier in The International Journal of Biochemistry & Cell Biology
- Vol. 134, 105971
Microvascular cells: A special focus on heterogeneity of pericytes in diabetes associated complications